Drug recall · March 27, 2019
Valsartan Tablets 40 mg USP recall
Why: CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Valsartan Tablets 40 mg USP, 30 tablet bottles, Rx, Only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ, Manufactured by: Aurolife Pharma LLC, Dayton, NJ ---- NDC 52343-122-30
- Lots / codes
470170038A, exp. date 10/31/2019 470180010A, exp. date 02/29/2019 470180012A, exp. date 03/31/2020
- Quantity
- 30,530 bottles
- Company
- Rising Pharmaceuticals, Inc., Saddle Brook, NJ
- Distribution
- Product was distributed to 6 major distributors who may have further distributed the product throughout the United States.
- Initiated
- March 7, 2019 · Voluntary: Firm initiated
- Classified
- March 21, 2019
- Reported
- March 27, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Valsartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.